Gabriella Massolini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gabriella Massolini has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Enrica Calleri
Department of Drug Sciences, University of Pavia, 27100 Pavia, Italy
19 shared publications - Caterina Temporini
Department of Drug Sciences, University of Pavia, Pavia, Italy
18 shared publications - Sara Tengattini
Department of Drug Sciences, University of Pavia, Pavia, Italy
7 shared publications - Ersilia De Lorenzi
Department of Drug Sciences Medicinal Chemistry and Pharmaceutical Technology Section University of Pavia Viale Taramelli 12 27100 Pavia Italy
5 shared publications - Gloria Brusotti
Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy
5 shared publications - Giorgio Marrubini
Department of Drug Sciences, University of Pavia, 27100 Pavia, Italy
4 shared publications
Latest Publications
- Open Access
- 23 May 2026
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 279, 117576
Systematic development and optimization of a cIEF method for the charge variants analysis of moderately basic to basic monoclonal antibodies using the Analytical Quality by Design strategy
- 23 May 2026
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 279, 117576
Open AccessSystematic development and optimization of a cIEF method for the charge variants analysis of moderately basic to basic monoclonal antibodies using the Analytical Quality by Design strategy
- 5 December 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (1) , 27
A Design of Experiments and Risk Management-Driven Analytical Platform for Charge Variant Analysis of Therapeutic Antibodies by Imaged Capillary Isoelectric Focusing
The evaluation of monoclonal antibodies (mAbs) charge variants during their entire life cycle is crucial, as their profiles represent a critical quality at
- 5 December 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (1) , 27
A Design of Experiments and Risk Management-Driven Analytical Platform for Charge Variant Analysis of Therapeutic Antibodies by Imaged Capillary Isoelectric Focusing
The evaluation of monoclonal antibodies (mAbs) charge variants during their entire life cycle is crucial, as their profiles represent a critical quality at
- Open Access
- 24 February 2024
- Published by Elsevier in Journal of Chromatography A
- Vol. 1720, 464771
Chromatographic separation by RPLC-ESI-MS of all hydroxyproline isomers for the characterization of collagens from different sources
- 24 February 2024
- Published by Elsevier in Journal of Chromatography A
- Vol. 1720, 464771
Open AccessChromatographic separation by RPLC-ESI-MS of all hydroxyproline isomers for the characterization of collagens from different sources
- Open Access
- 23 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (5) , 1321
Glycovaccine Design: Optimization of Model and Antitubercular Carrier Glycosylation via Disuccinimidyl Homobifunctional Linker
Conjugation via disuccinimidyl homobifunctional linkers is reported in the literature as a convenient approach for the synthesis of glycoconjugate vaccines. However, the high tendency for hydrolysis of disuccinimidyl linkers hampers their extensive purification, which unavoidably results in side-reactions and non-pure glycoconjugates. In this paper, conjugation of 3-aminopropyl saccharides via disuccinimidyl glutarate (DSG) was exploited for the synthesis of glycoconjugates. A model protein, ribonuclease A (RNase A), was first considered to set up the conjugation strategy with mono- to tri- mannose saccharides. Through a detailed characterization of synthetized glycoconjugates, purification protocols and conjugation conditions have been revised and optimized with a dual aim: ensure high sugar-loading and avoid the presence of side reaction products. An alternative purification approach based on hydrophilic interaction liquid chromatography (HILIC) allowed the formation of glutaric acid conjugates to be avoided, and a design of experiment (DoE) approach led to optimal glycan loading. Once its suitability was proven, the developed conjugation strategy was applied to the chemical glycosylation of two recombinant antigens, native Ag85B and its variant Ag85B-dm, that are candidate carriers for the development of a novel antitubercular vaccine. Pure glycoconjugates (≥99.5%) were obtained. Altogether, the results suggest that, with an adequate protocol, conjugation via disuccinimidyl linkers can be a valuable approach to produce high sugar-loaded and well-defined glycovaccines.
- 23 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (5) , 1321
Open AccessGlycovaccine Design: Optimization of Model and Antitubercular Carrier Glycosylation via Disuccinimidyl Homobifunctional Linker
Conjugation via disuccinimidyl homobifunctional linkers is reported in the literature as a convenient approach for the synthesis of glycoconjugate vaccines. However, the high tendency for hydrolysis of disuccinimidyl linkers hampers their extensive purification, which unavoidably results in side-reactions and non-pure glycoconjugates. In this paper, conjugation of 3-aminopropyl saccharides via disuccinimidyl glutarate (DSG) was exploited for the synthesis of glycoconjugates. A model protein, ribonuclease A (RNase A), was first considered to set up the conjugation strategy with mono- to tri- mannose saccharides. Through a detailed characterization of synthetized glycoconjugates, purification protocols and conjugation conditions have been revised and optimized with a dual aim: ensure high sugar-loading and avoid the presence of side reaction products. An alternative purification approach based on hydrophilic interaction liquid chromatography (HILIC) allowed the formation of glutaric acid conjugates to be avoided, and a design of experiment (DoE) approach led to optimal glycan loading. Once its suitability was proven, the developed conjugation strategy was applied to the chemical glycosylation of two recombinant antigens, native Ag85B and its variant Ag85B-dm, that are candidate carriers for the development of a novel antitubercular vaccine. Pure glycoconjugates (≥99.5%) were obtained. Altogether, the results suggest that, with an adequate protocol, conjugation via disuccinimidyl linkers can be a valuable approach to produce high sugar-loaded and well-defined glycovaccines.
- Open Access
- 10 March 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (6) , 4878
Synthesis, Characterization and Application of a MIP-polyHIPE for Selective Extraction of Angiotensin II Receptor Antagonists Residues in Natural Waters
Polymers via high internal phase emulsion (polyHIPEs) were molecularly imprinted with Irbesartan, an antihypertensive drug belonging to the class of angiotensin II receptor antagonists (sartan drugs), chosen for the proof-of-concept extraction of hazardous emerging contaminants from water. Different analyte-functional monomer molar ratios (1:100, 1:30 and 1:15) were investigated, and the MIP polyHIPEs have been characterized, parallel to the not imprinted polymer (NIP), by batch sorption experiments. The material with the highest template-functional monomer ratio was the best for Irbesartan removal, showing a sorption capacity fivefold higher than the NIP. Regarding the adsorption kinetics, the analyte–sorbent equilibrium was reached after about 3 h, and the film diffusion model best fitted the kinetic profile. Selectivity was further demonstrated by testing Losartan, another sartan drug, observing a fourfold lower sorption capacity, but still higher than that of NIP. The polymers were also synthesized in cartridges for solid-phase extraction (SPE), which was helpful for evaluating the breakthrough curves and performing pre-concentrations. These have been done in tap and river water samples (100–250 mL, 15–500 µg L−1 Irbesartan), obtaining quantitative sorption/desorption on the MIP-polyHIPE (RSD < 14%, n = 3). The NIP provided a recovery of just around 30%, evidence of partial uptake of the target from water.
- 10 March 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (6) , 4878
Open AccessSynthesis, Characterization and Application of a MIP-polyHIPE for Selective Extraction of Angiotensin II Receptor Antagonists Residues in Natural Waters
Polymers via high internal phase emulsion (polyHIPEs) were molecularly imprinted with Irbesartan, an antihypertensive drug belonging to the class of angiotensin II receptor antagonists (sartan drugs), chosen for the proof-of-concept extraction of hazardous emerging contaminants from water. Different analyte-functional monomer molar ratios (1:100, 1:30 and 1:15) were investigated, and the MIP polyHIPEs have been characterized, parallel to the not imprinted polymer (NIP), by batch sorption experiments. The material with the highest template-functional monomer ratio was the best for Irbesartan removal, showing a sorption capacity fivefold higher than the NIP. Regarding the adsorption kinetics, the analyte–sorbent equilibrium was reached after about 3 h, and the film diffusion model best fitted the kinetic profile. Selectivity was further demonstrated by testing Losartan, another sartan drug, observing a fourfold lower sorption capacity, but still higher than that of NIP. The polymers were also synthesized in cartridges for solid-phase extraction (SPE), which was helpful for evaluating the breakthrough curves and performing pre-concentrations. These have been done in tap and river water samples (100–250 mL, 15–500 µg L−1 Irbesartan), obtaining quantitative sorption/desorption on the MIP-polyHIPE (RSD < 14%, n = 3). The NIP provided a recovery of just around 30%, evidence of partial uptake of the target from water.
- 1 October 2021
- Published by Elsevier in TrAC Trends in Analytical Chemistry
- Vol. 143
Analytical settings for in-flow biocatalytic reaction monitoring
- 1 October 2021
- Published by Elsevier in TrAC Trends in Analytical Chemistry
- Vol. 143
Analytical settings for in-flow biocatalytic reaction monitoring
- Open Access
Bio-Guided Fractionation of Stem Bark Extracts from Phyllanthus muellarianus: Identification of Phytocomponents with Anti-Cholinesterase Activity
A combination of flash chromatography, solid phase extraction, high-performance liquid chromatography, and in vitro bioassays was used to isolate phytocomponents endowed with anticholinesterase activity in extract from Phyllanthus muellarianus. Phytocomponents responsible for the anti-cholinesterase activity of subfractions PMF1 and PMF4 were identified and re-assayed to confirm their activity. Magnoflorine was identified as an active phytocomponent from PMF1 while nitidine was isolated from PMF4. Magnoflorine was shown to be a selective inhibitor of human butyrylcholinesterase—hBChE (IC50 = 131 ± 9 μM and IC50 = 1120 ± 83 μM, for hBuChE and human acetylcholinesterase—hAChE, respectively), while nitidine showed comparable inhibitory potencies against both enzymes (IC50 = 6.68 ± 0.13 μM and IC50 = 5.31 ± 0.50 μM, for hBChE and hAChE, respectively). When compared with the commercial anti-Alzheimer drug galanthamine, nitidine was as potent as galanthamine against hAChE and one order of magnitude more potent against hBuChE. Furthermore, nitidine also showed significant, although weak, antiaggregating activity towards amyloid-β self-aggregation.
Open AccessBio-Guided Fractionation of Stem Bark Extracts from Phyllanthus muellarianus: Identification of Phytocomponents with Anti-Cholinesterase Activity
A combination of flash chromatography, solid phase extraction, high-performance liquid chromatography, and in vitro bioassays was used to isolate phytocomponents endowed with anticholinesterase activity in extract from Phyllanthus muellarianus. Phytocomponents responsible for the anti-cholinesterase activity of subfractions PMF1 and PMF4 were identified and re-assayed to confirm their activity. Magnoflorine was identified as an active phytocomponent from PMF1 while nitidine was isolated from PMF4. Magnoflorine was shown to be a selective inhibitor of human butyrylcholinesterase—hBChE (IC50 = 131 ± 9 μM and IC50 = 1120 ± 83 μM, for hBuChE and human acetylcholinesterase—hAChE, respectively), while nitidine showed comparable inhibitory potencies against both enzymes (IC50 = 6.68 ± 0.13 μM and IC50 = 5.31 ± 0.50 μM, for hBChE and hAChE, respectively). When compared with the commercial anti-Alzheimer drug galanthamine, nitidine was as potent as galanthamine against hAChE and one order of magnitude more potent against hBuChE. Furthermore, nitidine also showed significant, although weak, antiaggregating activity towards amyloid-β self-aggregation.
- 6 November 2020
- Published by Springer Nature in Food and Bioprocess Technology
- Vol. 13 (12) , 2120-2130
Assessment of the Bioactive Potential of Cheese Whey Protein Hydrolysates Using Immobilized Alcalase
- 6 November 2020
- Published by Springer Nature in Food and Bioprocess Technology
- Vol. 13 (12) , 2120-2130
Assessment of the Bioactive Potential of Cheese Whey Protein Hydrolysates Using Immobilized Alcalase
- 1 February 2020
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 179, 112920
Chromatographic tools for plant-derived recombinant antibodies purification and characterization
- 1 February 2020
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 179, 112920
Chromatographic tools for plant-derived recombinant antibodies purification and characterization
- Open Access
- 21 November 2019
- Published by MDPI AG in Proceedings
- Vol. 22 (1) , 109
Immobilized Enzyme Reactors Based on Nucleoside Phosphorylases (NPs) and Nucleoside 2′-Deoxyribosyltransferases (NDTs) for the In-Flow Synthesis of Nucleoside Analogues
Enzymes are increasingly used as biocatalysts for the production of Active Pharmaceutical
- 21 November 2019
- Published by MDPI AG in Proceedings
- Vol. 22 (1) , 109
Open AccessImmobilized Enzyme Reactors Based on Nucleoside Phosphorylases (NPs) and Nucleoside 2′-Deoxyribosyltransferases (NDTs) for the In-Flow Synthesis of Nucleoside Analogues
Enzymes are increasingly used as biocatalysts for the production of Active Pharmaceutical